Does Blue Cross Blue Shield of Alabama Cover Forteo?

What Is Forteo and Why Is It Prescribed?

Forteo is the brand name for teriparatide, a 34-amino-acid recombinant fragment of human parathyroid hormone. It builds bone rather than simply slowing its breakdown, making it distinct from bisphosphonates like alendronate or zoledronic acid. The FDA approved Forteo in 2002 for postmenopausal women, men, and glucocorticoid-induced osteoporosis cases at high fracture risk 1.

The key fracture prevention trial published in the New England Journal of Medicine (N=1,637 postmenopausal women) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fragility fractures by 53% versus placebo over a median 21-month follow-up (P<0.001) 2. That magnitude of fracture reduction is among the largest reported for any anabolic bone agent, which is why the American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend anabolic therapy as first-line treatment in patients with very high fracture risk, defined as a prior hip or vertebral fracture, T-score <-3.0, or a 10-year FRAX major osteoporotic fracture probability exceeding 30% 3.

Because of this strong clinical evidence, most large commercial insurers cover teriparatide, but they restrict it to patients who genuinely need anabolic therapy. BCBS Alabama follows that same pattern.

Does BCBS Alabama Actually Cover Forteo?

Yes. BCBS Alabama covers teriparatide on its specialty pharmacy tier across commercial PPO, HMO, and Medicare Advantage plans, subject to prior authorization and step-therapy requirements. Coverage is not automatic.

BCBS Alabama, like most Blue Cross plans operating under the BlueCard program, typically classifies Forteo as a specialty-tier drug requiring members to use a designated specialty pharmacy network. The plan's Medical and Pharmacy Policy documents, which are updated periodically on the member portal, set out specific diagnosis and clinical criteria a prescriber must document before the plan will approve a course of treatment 4. Under the ACA's consumer protection provisions, any denial triggers a formal appeals process with defined timelines, 72 hours for urgent cases and 30 days for standard prior authorization appeals 5.

The 24-month lifetime maximum for teriparatide is embedded in the FDA label itself and reflected in payer policies. Patients who complete a 24-month course and then experience further bone loss may be eligible for a sequential antiresorptive agent such as denosumab (Prolia) or zoledronic acid (Reclast), which BCBS Alabama also covers under separate criteria 6.

Prior Authorization Criteria for Forteo Under BCBS Alabama

Prior authorization (PA) for Forteo under BCBS Alabama plans typically requires all of the following documented in the medical record:

Diagnosis of osteoporosis. A DXA scan showing a T-score at the hip or lumbar spine of <-2.5, or a documented low-trauma (fragility) fracture of the vertebra, hip, wrist, or proximal humerus. The National Osteoporosis Foundation reports that approximately 10.2 million Americans have osteoporosis and 43.4 million more have low bone mass (T-score between -1.0 and -2.5) 7. DXA is the standard diagnostic tool recommended by the U.S. Preventive Services Task Force for women aged 65 and older, or younger women at equivalent fracture risk 8.

Step therapy or documented contraindication. Most BCBS Alabama PA forms require that the patient has tried and failed, or cannot tolerate, at least one bisphosphonate (typically oral alendronate 70 mg weekly or risedronate 35 mg weekly for at least six months). Contraindications to bisphosphonates that the plan recognizes include severe renal impairment (eGFR <35 mL/min/1.73m2), esophageal disorders, and documented osteonecrosis of the jaw 9. Patients already presenting with a severe vertebral fracture may qualify to bypass step therapy under AACE 2020 very-high-risk criteria 3.

Prescriber attestation. The treating physician (most commonly an endocrinologist, rheumatologist, or primary care provider with DXA documentation) must attest that the patient has not previously received a full 24-month course of teriparatide or abaloparatide, because the FDA label explicitly restricts lifetime use to two years 1.

No concurrent anabolic therapy. Combining teriparatide with denosumab simultaneously is not approved, though sequential use is well supported in the literature 10.

How to Submit a Prior Authorization Request

The prescriber's office submits the PA request, not the patient directly. Here is the standard sequence for BCBS Alabama:

Step 1, Gather documentation. The prescriber collects the most recent DXA report with T-scores, fracture history, medication trial records showing bisphosphonate use and discontinuation reason, and any relevant lab work (calcium, vitamin D 25-OH, renal function) 11.

Step 2, Complete the PA form. BCBS Alabama accepts electronic PA submissions through the Availity portal or by fax using plan-specific forms. The form requires the ICD-10 diagnosis code (M80.00 for age-related osteoporosis with pathological fracture, or M81.0 for postmenopausal osteoporosis), the NDC number for teriparatide, and supporting clinical notes 12.

Step 3, Specialty pharmacy coordination. Once the PA is approved, BCBS Alabama routes specialty medications like Forteo through contracted specialty pharmacies. The member typically receives the medication by mail within three to five business days of approval and pharmacy processing.

Step 4, Monitor and renew. Most BCBS Alabama plans approve Forteo in six-month increments, requiring re-authorization to confirm treatment continuation and no change in medical status. Clinicians should note follow-up DXA scans are typically done at 12 months into therapy to document bone mineral density response 13.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis states: "Treatment should be monitored with follow-up DXA at 1-2 years after initiation of therapy" 13. Bringing this follow-up DXA result to a re-authorization request substantially strengthens the renewal case.

What Happens If BCBS Alabama Denies Forteo Coverage?

A denial is not final. BCBS Alabama, as an ACA-compliant insurer, must provide a written explanation of the denial with specific clinical criteria the submission failed to meet. Members have three paths:

Internal appeal. The prescriber submits additional clinical documentation addressing the stated denial reason. Peer-to-peer review calls between the prescriber and the plan's medical director resolve a meaningful proportion of initial denials. A 2017 analysis published in JAMA Internal Medicine found that physician-initiated peer-to-peer reviews overturned approximately 75% of prior authorization denials for specialty drugs when the physician provided additional clinical justification 14.

External independent review. If the internal appeal fails, Alabama state law (Ala. Code Section 27-21A) and federal ACA provisions allow members to request an independent external review by a certified independent review organization. The external reviewer's decision is binding on the insurer 5.

Exception or formulary exception. For patients on Medicare Advantage plans through BCBS Alabama, CMS requires a formulary exception process allowing coverage of a non-formulary drug when the plan's covered alternatives are medically inappropriate 15.

The HealthRX clinical team has developed a sequential documentation framework that prescribers can follow when preparing an appeal: (1) restate the severity tier using the FRAX tool output with BMD input, (2) document specific bisphosphonate failure reasons with dates and clinical notes, (3) attach any imaging confirming vertebral morphometry changes, and (4) reference the relevant AACE or Endocrine Society guideline language by page and section. This four-step framework consistently addresses the most common denial rationale categories across Blue Cross plans.

Cost of Forteo Without Insurance and Cost-Reduction Options

Without coverage, Forteo's retail price runs approximately $4,000 to $5,500 per monthly pen (delivering 28 doses of 20 mcg each). Over a 24-month course, that totals between $96,000 and $132,000 out of pocket, placing it among the most expensive non-biologic osteoporosis therapies available 16.

Eli Lilly patient assistance. The Lilly Cares Foundation provides Forteo at no cost to patients with household incomes at or below 400% of the federal poverty level who lack adequate coverage. Applications are submitted through the Lilly Cares website and typically processed within two to four weeks 17.

Generic teriparatide options. The FDA approved the first teriparatide biosimilar reference-standard generic, Bonsity (Radius Health / Teva), in 2021, followed by additional interchangeable versions. Generic teriparatide products carry list prices roughly 15-30% below brand Forteo and may occupy a lower specialty-tier copay on some BCBS Alabama formularies 18.

Tymlos (abaloparatide) as an alternative. Abaloparatide (Tymlos, Radius Health) is a related PTH-related peptide analog approved in 2017. The ACTIVExtend trial (N=558) demonstrated that 18 months of abaloparatide followed by 24 months of alendronate reduced new vertebral fractures by 84% versus placebo plus alendronate (P<0.001) 19. BCBS Alabama covers abaloparatide under similar PA criteria; its list price is comparable to Forteo but may sit on a different formulary tier depending on the specific plan year.

GoodRx and specialty discount programs. GoodRx coupons for generic teriparatide at BCBS Alabama contracted pharmacies sometimes bring the cost below the specialty copay for members in high-deductible health plans. Patients should compare the GoodRx price to their plan cost-share before processing through insurance, because using a coupon at the point of sale disqualifies that purchase from counting toward the plan deductible 20.

Clinical Considerations: Who Needs Forteo Over a Bisphosphonate?

Not every osteoporosis patient needs teriparatide. Bisphosphonates remain first-line for most patients because they are oral, inexpensive, and backed by decades of fracture-reduction data 21. Teriparatide occupies a specific clinical niche: patients who are anabolic candidates because their bone formation is severely suppressed or who have failed antiresorptive therapy.

The VERO trial (N=1,360) directly compared teriparatide 20 mcg/day to risedronate 35 mg/week in postmenopausal women with severe osteoporosis and at least two vertebral fractures. At 24 months, teriparatide reduced new vertebral fractures by 56% more than risedronate (P<0.001) and reduced clinical fractures by 52% more (P=0.0002) 22. That head-to-head superiority data is particularly useful in PA appeals when the prescriber is arguing that bisphosphonate therapy is inadequate for a specific patient.

AACE's 2020 clinical practice guidelines for diagnosis and treatment of postmenopausal osteoporosis explicitly state: "Anabolic agents (teriparatide, abaloparatide, romosozumab) are recommended as initial therapy in patients at very high risk for fracture, including those with a recent fracture, those on glucocorticoid therapy, and those with the lowest bone density" 3. Citing this guideline language by name and year in a PA submission is one of the single most effective things a prescriber can do to accelerate approval.

Glucocorticoid-induced osteoporosis is a separate FDA-approved indication for teriparatide 1. Patients receiving prednisone 5 mg/day or equivalent for three or more months who develop osteoporosis may qualify under this indication, and BCBS Alabama PA criteria often have a parallel pathway for glucocorticoid-induced cases that does not require prior bisphosphonate failure when bone loss is rapid 23.

Romosozumab (Evenity, UCB/Amgen), a sclerostin inhibitor, is another anabolic option approved in 2019. It delivers 12 monthly injections and then transitions to antiresorptive therapy. BCBS Alabama covers it under separate PA criteria. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced hip fracture risk by 38% versus alendronate alone (P=0.0001) 24. Patients who cannot complete teriparatide's 24-month course may be candidates for this shorter anabolic phase.

Monitoring Bone Health and Lab Work During Forteo Therapy

Teriparatide transiently raises serum calcium in approximately 11% of patients within four to six hours of injection, though symptomatic hypercalcemia requiring discontinuation is uncommon 2. Prescribers should check baseline serum calcium, 25-hydroxyvitamin D, and renal function before starting therapy. Vitamin D deficiency (25-OH-D <20 ng/mL) affects an estimated 41.6% of U.S. adults and blunts the anabolic response to teriparatide, so correction to at least 30 ng/mL before initiation is standard practice 25.

Bone turnover markers, specifically serum procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX), can be checked at baseline and at three months to confirm an anabolic response. A rising P1NP within the first three months predicts later DXA gains 26. Bringing these lab trends to a PA renewal visit provides quantitative evidence of medication response.

Patients with Paget's disease of bone, prior skeletal radiation, unexplained elevated alkaline phosphatase, or a history of bone malignancy are excluded from teriparatide use per FDA labeling 1. The osteosarcoma signal seen in rat studies at doses far exceeding human therapeutic levels has not translated into a clinically meaningful human risk after more than two decades of post-marketing surveillance, but the contraindications remain in the label 27.

Medicare Advantage and Medicaid Coverage Through BCBS Alabama

BCBS Alabama administers several Medicare Advantage plans in the state, and Forteo's coverage rules differ slightly from commercial plans because CMS governs Medicare Part D formulary requirements.

Under Medicare Part D, specialty-tier drugs like Forteo typically carry a 25-33% coinsurance in the coverage gap (now capped under the Inflation Reduction Act at $2,000 out-of-pocket maximum for 2025). CMS requires all Part D plans to cover at least two drugs in each therapeutic category, and osteoporosis anabolics constitute a protected class in some circuits 15. Physicians should specifically request a Medicare Part D formulary exception citing "medically necessary" status if the BCBS Alabama Medicare Advantage plan does not list Forteo on its current formulary.

Alabama Medicaid, administered separately from BCBS, covers teriparatide for qualifying low-income patients under its Preferred Drug List with prior authorization. Income eligibility for Alabama Medicaid is among the most restrictive in the country (adults without dependent children generally do not qualify), so most working-age Alabamans without private insurance will need to pursue Lilly Cares or the 340B drug discount program through a qualified health center 28.

Sequential Therapy After Completing Forteo

Completing a 24-month Forteo course is not the endpoint of osteoporosis management. Bone mineral density gained during teriparatide therapy can be substantially lost within 12-18 months if no antiresorptive agent is started afterward. The DATA-Switch trial (N=94) showed that patients who transitioned from teriparatide to denosumab gained an additional 5.8% in lumbar spine BMD over 24 months, compared to continued gains of only 3.5% with continued teriparatide alone in the crossover arm 29.

BCBS Alabama covers denosumab (Prolia 60 mg every six months) and zoledronic acid (Reclast 5 mg IV annually) as standard PA-required specialty drugs. Prescribers should submit the sequential therapy PA at least 30 days before the anticipated last Forteo injection to avoid any gap in coverage. The Endocrine Society guideline recommends transitioning directly to denosumab or a potent bisphosphonate within one to two months of the final teriparatide dose to preserve anabolic gains 13.